Fortis Group Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.03K Hold
13
﹤0.01% 444
2026
Q1
$3.81K Hold
13
﹤0.01% 455
2025
Q4
$4.56K Hold
13
﹤0.01% 439
2025
Q3
$4.2K Hold
13
﹤0.01% 406
2025
Q2
$5.06K Hold
13
﹤0.01% 386
2025
Q1
$5.65K Hold
13
﹤0.01% 347
2024
Q4
$4.8K Hold
13
﹤0.01% 366
2024
Q3
$6.76K Hold
13
﹤0.01% 330
2024
Q2
$7.04K Hold
13
﹤0.01% 326
2024
Q1
$6.74K Sell
13
-13
-50% -$6.46K ﹤0.01% 348
2023
Q4
$12.3K Buy
26
+13
+100% +$6.01K ﹤0.01% 278
2023
Q3
$5.66K Buy
+13
New +$5.9K ﹤0.01% 277

Other funds holding ELV

Fortis Group Advisors's ELV Position: Q2 2026 in Review

Fortis Group Advisors held its Elevance Health (ELV) position steady in Q2 2026 at 13 shares worth $5.03K. The position accounts for ﹤0.01% of the portfolio, ranked #444.

Fortis Group Advisors first reported a position in ELV in Q3 2023 and has held it in 12 quarters since. The position peaked at $12.3K in Q4 2023. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Fortis Group Advisors held 13 shares of Elevance Health worth $5.03K as of Q2 2026.
  • Fortis Group Advisors left its Elevance Health share count unchanged in Q2 2026.
  • Elevance Health made up ﹤0.01% of Fortis Group Advisors's portfolio in Q2 2026, its #444 holding.
  • Fortis Group Advisors first reported a position in Elevance Health in Q3 2023 and has held it in 12 quarters since.
  • Fortis Group Advisors's Elevance Health position peaked at $12.3K in Q4 2023.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Fortis Group Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.